<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: Recent reports suggest that vascular factors play a crucial role in the development and progression of <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We aimed to assess vasomotor reactivity in patients with <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> and vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> due to <z:e sem="disease" ids="C0155765" disease_type="Disease or Syndrome" abbrv="">microangiopathy</z:e> using transcranial Doppler sonography and near-infrared spectroscopy during a <z:chebi fb="0" ids="16526">CO(2)</z:chebi> exposition task </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: The normalized <z:chebi fb="0" ids="16526">CO(2)</z:chebi> reactivity assessed at the middle cerebral artery and the oxygenated and deoxygenated <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> of the frontal cortex were obtained </plain></SENT>
<SENT sid="3" pm="."><plain>To investigate the impact of cholinergic deficiency known for <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> on vasomotor reactivity, both groups were reinvestigated during treatment with the <z:chebi fb="0" ids="38462">acetylcholine esterase inhibitor</z:chebi> galantamine </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Transcranial Doppler analysis revealed significantly reduced normalized <z:chebi fb="0" ids="16526">CO(2)</z:chebi> reactivity for <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> and vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Vasomotor reactivity assessed by near-infrared spectroscopy was decreased in patients with vascular <z:hpo ids='HP_0000726'>dementia</z:hpo>, but not in <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Galantamine treatment showed a beneficial effect, normalizing these parameters close to age-matched control levels </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: Our results suggest that <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> is associated with a lack of vasomotor reactivity, which might be associated with disturbed autoregulation indicating a potential risk for a decreased protection of brain tissue against blood pressure changes </plain></SENT>
<SENT sid="8" pm="."><plain>Additionally, a diminished increase of cortical oxygenated <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> during the <z:chebi fb="0" ids="16526">CO(2)</z:chebi> test was apparent in patients with vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Galantamine treatment influenced vascular reactivity in the <z:chebi fb="0" ids="16526">CO(2)</z:chebi> test, thus providing evidence for the cholinergic deficiency, thereby adding to vascular dysregulation in <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e>, but also indicating an important role of cholinergic system dysfunction for vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
</text></document>